Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from enGene Holdings ( (ENGN) ) is now available.
enGene Holdings Inc. announced a conference call to discuss new preliminary data from the pivotal cohort of its LEGEND trial, focusing on the gene therapy candidate detalimogene voraplasmid for high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer. This announcement highlights the company’s ongoing efforts to advance its genetic medicine pipeline and potentially improve treatment options for patients with significant unmet medical needs.
The most recent analyst rating on (ENGN) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
enGene Holdings shows significant financial challenges, with no revenue generation and persistent losses impacting both income and cash flow statements. Technical indicators suggest bearish momentum, with the stock underperforming key moving averages. The valuation is further hampered by a negative P/E ratio and absence of dividends. These factors collectively result in a low overall stock score, highlighting the company’s urgent need to establish a revenue model and improve operational efficiency.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Holdings Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines. The company specializes in delivering therapeutics to mucosal tissues and other organs to address diseases with significant clinical needs. Its lead program, detalimogene voraplasmid, targets Non-Muscle Invasive Bladder Cancer (NMIBC) and is being evaluated in the LEGEND Phase 2 trial.
Average Trading Volume: 273,375
Technical Sentiment Signal: Buy
Current Market Cap: $310.2M
For detailed information about ENGN stock, go to TipRanks’ Stock Analysis page.